Free Subscription

  • Access 15 free news articles each month

Professional

Try one month for $5
  • Unlimited access to news,insights and opinions
  • Quarterly and weekly magazines
  • Independent research reports and forecasts
  • Quarterly webinars with industry experts
  • Q&A with retail leaders
  • Career advice
  • Exclusive Masterclass access. Part of Retail Week 2021

OTC cannabidiol set to open $200m market – but is there evidence to back it up?

A picture of a marijuana leaf lying on top of a cardboard box
The decision means consumers will have easier access to cannabidol products. Image: Unsplash
The Australian Therapeutic Goods Administration’s (TGA) landmark interim decision to make registered low-dose cannabidiol (CBD) products available in pharmacies could open up a market worth more than $200 million, according to a Q3 report by medicinal cannabis experts Fresh Leaf Analytics.  The proposed new regulations mean that companies could apply for Schedule 3 (S3) or “over the counter” registration for oral or oromucosal CBD products such as oils, capsules, sprays and wafers, as ear

Masterclasses are for professionals only

Only $5 p/m for first 3 months
Become a Professional Already a professional? Login
  • Daily exclusive Members Only content straight to your inbox
  • Access to exclusive Retail Week events including all 4 Masterclasses 28 February - 3 March
  • Retail insights and intelligence
  • On-demand videos with industry professionals
  • Weekly careers advice specific to retailers
  • Independent research reports and forecasts
  • Q&A with industry experts
  • Content, content, content! Weekly and quarterly magazines